Navigation Links
Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
Date:12/2/2009

court judgment finding the patents invalid or not infringed or 30 months from the company's October 2009 receipt of a Paragraph IV certification letter from Teva.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL (armodafinil) Tablets [C-IV], TREANDA® (bendamustine hydrochloride) for Injection, AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), FENTORA® (fentanyl buccal tablet) [C-II], TRISENOX® (arsenic trioxide) injection, GABITRIL® (tiagabine hydrochloride), PROVIGIL® (modafinil) Tablets [C-IV] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
2. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
3. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
4. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
5. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
6. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
9. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
10. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
11. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... 2010 Abbott Diabetes Care today announced that it ... million strips) of Precision Xtra®, Precision Xceed Pro®, MediSense® ... Strips in the United States and Puerto Rico. ... Precision Xtra, Precision Xceed Pro, MediSense Optium, Optium and ...
... 2010 Heska Corporation (Nasdaq: HSKA ) announces ... to Its Special Meeting of Stockholders on the WebWhen: , ... (click on the Special Meeting of Stockholders link on ... Internet -- Simply log on to the web at the ...
Cached Medicine Technology:Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 2Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 3Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 4Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 5Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 6Webcast Alert: Heska Corporation's Special Meeting of Stockholders Webcast 2
(Date:4/22/2014)... are more likely to have a child who develops ... A recent study from researchers from the Drexel University ... in Sweden provides more insight into how the risk ... ages, and found that the risk of having a ... for older parents., In the study, published in the ...
(Date:4/22/2014)... Based on results of a clinical trial led ... and Drug Administration (FDA) approved a molecularly targeted ... that has progressed after standard chemotherapy has failed. ... was announced by the manufacturer, Lilly Oncology, of ... ramucirumab, it will be sold under the name ...
(Date:4/22/2014)... identify patients who are at highest risk for respiratory ... condition, suggest data from a large multi-center study published ... Affecting nearly 200,000 Americans a year, acute respiratory distress ... caused by a number of issues ranging from smoke ... develop ARDS after surgery. ARDS is difficult to treat ...
(Date:4/22/2014)... out of the University of Calgary,s Hotchkiss Brain Institute ... nerve cells as a means to restore connections after ... a key molecule that directly regulates nerve cell growth ... in the prestigious journal Nature Communications , with ... "We made the surprising discovery that a protein ...
(Date:4/21/2014)... ROCHESTER, Minn. Acute respiratory distress syndrome is ... Patients who develop the lung disorder postoperatively are ... and those who survive the syndrome may still ... A Mayo Clinic-led study is helping physicians better ... toward preventing this dangerous and costly surgical complication. ...
Breaking Medicine News(10 mins):Health News:Child's autism risk accelerates with mother's age over 30 2Health News:Child's autism risk accelerates with mother's age over 30 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:New tool helps doctors better predict, prevent deadly respiratory failure 2Health News:Scientists discover a new way to enhance nerve growth following injury 2Health News:Acute respiratory distress syndrome: Study IDs surgical patients at risk 2
... that Snake Bites are Becoming More Powerful and Patient Reactions ... marks a change in rattlesnake behavior as well. Snakes ... the rattlesnake is. In humans, a rattlesnake bite can ... the past couple of years we have seen an increase ...
... 5 Argus Health Systems, Inc., a leading provider ... Topor has been elected to the National Council for ... three-year term. The Board of Trustees oversees all Council ... development activities. Prior to the election, Topor, a 12-year ...
... support the use of lower cost sharing as an incentive ... in order to reduce costs, according to survey data published ... have been interested in bringing aspects of "consumerism" into health ... 2009 EBRI Notes , which reports the survey data. ...
... aggressive goals to expand nationwide, Wellspring ... Development. Bill will spearhead the newly formed Network Development Division ... in 2010. He is responsible for making Wellspring a household ... former Fortune 100 senior executive with healthcare, insurance and leading ...
... revenues grow by 31% and gross profit increases 85%ROCHESTER, N.Y., ... a leading provider of quantitative imaging for clinical trials, announced ... over $2.1 million, a 31% increase over prior year,s first ... was $1,119,786 compared to $604,119 in the first quarter of ...
... Advisory Board Will Host ,Day of Dialogue, Online Town Hall ... 5, 2009 America,s healthcare and long-term services need to ... of today,s seniors and people with disabilities, according to a ... The report, which will be supported by a nationwide ...
Cached Medicine News:Health News:As the Weather Warms Up Rattlesnakes Come Out to Enjoy the Sun Just as Californians Do 2Health News:New Research from EBRI: Many Support Lower Cost Sharing to Change Health Care System Use 2Health News:Wellspring Hires William Young and Prepares for Nationwide Expansion 2Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 2Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 3Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 4Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 5Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 6Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 2Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 3
PremierEdge Stab Knives - 15....
DCR Set, Straight....
... CORNEO-GAGE PLUS pachometers are acknowledged to be ... measurement-reproducible pachometers available. These benefits are due ... transducers and smallest tip footprint available coupled ... average for every displayed reading. Thus corneal ...
... Leica CM1850 cryostat for standard ... laboratory is designed for easy ... A new insulation technology used, ... refrigerating system and maintains stable ...
Medicine Products: